2027 Q3 - tulosraportti
UUTTA
2 päivää sitten
‧48 min
0,25 USD/osake
Viimeisin osinko
0,32%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Tuotteita joiden kohde-etuutena tämä arvopaperi
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q4 - tulosraportti 24.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2027 Q3 - tulosraportti 17.11. | ||
2027 Q2 - tulosraportti 26.8. | ||
Vuosittainen yhtiökokous 2026 24.6. | ||
2027 Q1 - tulosraportti 20.5. | ||
2026 Q4 - tulosraportti 25.2. |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenIn these times it is worth remembering why we believe in NVIDIA for the long term. Part of the potential lies in what the combination of future computing power, AI models and biological knowledge can make possible — and how NVIDIA may choose to monetize it. NVIDIA and Eli Lilly have announced a joint AI research laboratory with investments of up to $1 billion combined over five years, where biological and chemical models will be developed in close interplay with laboratory experiments. Together with Novo Nordisk and DCAI, NVIDIA is working around the Gefion supercomputer on, among other things, molecular design and models of cellular responses to drug candidates. The collaboration with the Chan Zuckerberg Initiative includes virtual cell models, biological datasets and evaluation of model quality. Biological complexity explains why the opportunities are vast and why development takes time. Proteins move, change shape and bind to other molecules. Inside the cell, gene activity, protein production, metabolism and chemical reactions influence each other. A change in one place can have consequences in many other places. Therefore, knowing a protein's structure is only part of the task. The time scales are also demanding. With a detailed molecular simulation using time steps of 2 femtoseconds, just one millisecond of the molecular trajectory requires 500 billion calculation steps, with many calculations in each step. This illustrates the challenge of this method; future models do not necessarily need to calculate every single atomic movement. At the same time, there is a lack of experimental data showing how different cells respond to stimuli, which can be used to develop and test the models. The collaborations can therefore both improve the technology and help identify the research problems where better computations create the greatest value. Models and computing power must evolve together. Even an extremely fast chip does not automatically create a correct model of biology. Conversely, a good model can be impractical if calculations take too long. When better chips are combined with more efficient algorithms and better biological models, increasingly demanding research tasks can become practically viable. As a hypothetical, optimistic scenario, this combined development over approximately 10–15 years could make selected calculation tasks 100 times faster, provided the results remain sufficiently reliable for the purpose. A task that would otherwise require ten years of computation could then be completed in about five weeks. This is a sample calculation and an estimated time horizon, not a forecast from NVIDIA. Valuable improvements may come much earlier, while laboratory work and clinical trials continue to follow their own timelines. The pace of development is therefore interesting. NVIDIA plans platform updates on an annual rhythm. Vera Rubin has begun shipping, while Rubin Ultra and Feynman lie further ahead in the development roadmaps. Additionally, the company has announced Rubin HPC, targeted at scientific simulations and expected to be available in 2028. Continuing in the next comment:Selling advanced chips and sharing tools today is strategic, but it does not permanently define the business model. For example, the BioNeMo Framework is currently free and open. This approach can drive adoption, experience, and demand for hardware. NVIDIA can thus profit from the research of many companies while building competencies and new opportunities. Over the longer term, NVIDIA could consolidate its own models, relevant data, and specialized research methods within its own research data centers, perhaps gaining an edge through early access to upcoming chip generations. Control over both hardware and software could provide advantages in customization and costs. Computing power would still cost money, and internal use would have to be attractive compared to selling the hardware. If this combined research capacity became sufficiently valuable, NVIDIA could choose to keep specific parts of the technology internal, use them for its own projects, and sell access to the computations. This could still be combined with extensive chip sales to others. If the platform also led to promising drug candidates of its own, the rights could be licensed in exchange for fees and royalties. Pharmaceutical companies could handle further development, clinical trials, approval, production, and sales. NVIDIA could thus generate revenue from hardware, the research platform, and concrete discoveries alike. Significant value can emerge through specialized models along the way toward a potentially more comprehensive simulator of cells and the human body. The entire vision does not need to be realized before the opportunities become interesting. This is an optimistic hypothesis regarding the opportunities NVIDIA can build—not a documented plan for a secret simulator. However, today's strategy can create the prerequisites for a different strategy later. The fact that it is attractive to sell the technology now does not mean it will always be most attractive to sell all parts of it. Jensen Huang has been central in shaping NVIDIA. However, belief in the company's future does not need to depend on him personally remaining at the helm the entire way. The technological direction is already visible in the chip pipeline, software platforms, and research collaborations, and the work is carried by an entire organization. The major breakthroughs still need to be created, but the foundation is laid, and the next stages are already under development. Jensen has helped chart the path; NVIDIA can continue the work of turning the vision into reality. Selected Sources NVIDIA and Eli Lilly's research collaboration, the collaboration with Novo Nordisk and DCAI, GROMACS for molecular simulation and timescales, NVIDIA's Vera Rubin platform and further development, as well as Rubin HPC for scientific simulations.
- ·6 t sittenIt is over! sell sell sell!!
- ·6 t sittenI am no expert but I think Nvidia is bought/sold for 2 reasons anthropic Jensen. I have been sitting and watching CNBC a lot the last few days and a lot has been about Jensen to be or not to be and if the Nvidia stock continues to plunge. And the new CEO's brutally bad conference speech from the board yesterday which was thought to be less gifted to comment on Jensen's situation since you don't know that much overall and they mean that is a part of the plunge we got to see today. So right now Nvidia is not traded on its numbers more on how the situation is and how it is handled. But as I said I am no expert we can hope for a day tomorrow.Nvidia is a winner and will probably not get much cheaper than what it is now I think, but there will be unrest in the ranks when you remove the genius in the company and replace him with the girl in the accounting department. Nvidia can be compared to the 90s Chicago Bulls until a few days ago. Chicago wins 6 championships during the 90s and suddenly someone gets the bright idea to remove Michael Jordan and then everything collapsed and they haven't won since and it's on those premises this stock is traded right now I think therefore the numbers don't seem to matter very much. So either you produce a new genius or you bring back the old genius but if you drag this out I think it will become problematic for everyone involved.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2027 Q3 - tulosraportti
UUTTA
2 päivää sitten
‧48 min
0,25 USD/osake
Viimeisin osinko
0,32%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenIn these times it is worth remembering why we believe in NVIDIA for the long term. Part of the potential lies in what the combination of future computing power, AI models and biological knowledge can make possible — and how NVIDIA may choose to monetize it. NVIDIA and Eli Lilly have announced a joint AI research laboratory with investments of up to $1 billion combined over five years, where biological and chemical models will be developed in close interplay with laboratory experiments. Together with Novo Nordisk and DCAI, NVIDIA is working around the Gefion supercomputer on, among other things, molecular design and models of cellular responses to drug candidates. The collaboration with the Chan Zuckerberg Initiative includes virtual cell models, biological datasets and evaluation of model quality. Biological complexity explains why the opportunities are vast and why development takes time. Proteins move, change shape and bind to other molecules. Inside the cell, gene activity, protein production, metabolism and chemical reactions influence each other. A change in one place can have consequences in many other places. Therefore, knowing a protein's structure is only part of the task. The time scales are also demanding. With a detailed molecular simulation using time steps of 2 femtoseconds, just one millisecond of the molecular trajectory requires 500 billion calculation steps, with many calculations in each step. This illustrates the challenge of this method; future models do not necessarily need to calculate every single atomic movement. At the same time, there is a lack of experimental data showing how different cells respond to stimuli, which can be used to develop and test the models. The collaborations can therefore both improve the technology and help identify the research problems where better computations create the greatest value. Models and computing power must evolve together. Even an extremely fast chip does not automatically create a correct model of biology. Conversely, a good model can be impractical if calculations take too long. When better chips are combined with more efficient algorithms and better biological models, increasingly demanding research tasks can become practically viable. As a hypothetical, optimistic scenario, this combined development over approximately 10–15 years could make selected calculation tasks 100 times faster, provided the results remain sufficiently reliable for the purpose. A task that would otherwise require ten years of computation could then be completed in about five weeks. This is a sample calculation and an estimated time horizon, not a forecast from NVIDIA. Valuable improvements may come much earlier, while laboratory work and clinical trials continue to follow their own timelines. The pace of development is therefore interesting. NVIDIA plans platform updates on an annual rhythm. Vera Rubin has begun shipping, while Rubin Ultra and Feynman lie further ahead in the development roadmaps. Additionally, the company has announced Rubin HPC, targeted at scientific simulations and expected to be available in 2028. Continuing in the next comment:Selling advanced chips and sharing tools today is strategic, but it does not permanently define the business model. For example, the BioNeMo Framework is currently free and open. This approach can drive adoption, experience, and demand for hardware. NVIDIA can thus profit from the research of many companies while building competencies and new opportunities. Over the longer term, NVIDIA could consolidate its own models, relevant data, and specialized research methods within its own research data centers, perhaps gaining an edge through early access to upcoming chip generations. Control over both hardware and software could provide advantages in customization and costs. Computing power would still cost money, and internal use would have to be attractive compared to selling the hardware. If this combined research capacity became sufficiently valuable, NVIDIA could choose to keep specific parts of the technology internal, use them for its own projects, and sell access to the computations. This could still be combined with extensive chip sales to others. If the platform also led to promising drug candidates of its own, the rights could be licensed in exchange for fees and royalties. Pharmaceutical companies could handle further development, clinical trials, approval, production, and sales. NVIDIA could thus generate revenue from hardware, the research platform, and concrete discoveries alike. Significant value can emerge through specialized models along the way toward a potentially more comprehensive simulator of cells and the human body. The entire vision does not need to be realized before the opportunities become interesting. This is an optimistic hypothesis regarding the opportunities NVIDIA can build—not a documented plan for a secret simulator. However, today's strategy can create the prerequisites for a different strategy later. The fact that it is attractive to sell the technology now does not mean it will always be most attractive to sell all parts of it. Jensen Huang has been central in shaping NVIDIA. However, belief in the company's future does not need to depend on him personally remaining at the helm the entire way. The technological direction is already visible in the chip pipeline, software platforms, and research collaborations, and the work is carried by an entire organization. The major breakthroughs still need to be created, but the foundation is laid, and the next stages are already under development. Jensen has helped chart the path; NVIDIA can continue the work of turning the vision into reality. Selected Sources NVIDIA and Eli Lilly's research collaboration, the collaboration with Novo Nordisk and DCAI, GROMACS for molecular simulation and timescales, NVIDIA's Vera Rubin platform and further development, as well as Rubin HPC for scientific simulations.
- ·6 t sittenIt is over! sell sell sell!!
- ·6 t sittenI am no expert but I think Nvidia is bought/sold for 2 reasons anthropic Jensen. I have been sitting and watching CNBC a lot the last few days and a lot has been about Jensen to be or not to be and if the Nvidia stock continues to plunge. And the new CEO's brutally bad conference speech from the board yesterday which was thought to be less gifted to comment on Jensen's situation since you don't know that much overall and they mean that is a part of the plunge we got to see today. So right now Nvidia is not traded on its numbers more on how the situation is and how it is handled. But as I said I am no expert we can hope for a day tomorrow.Nvidia is a winner and will probably not get much cheaper than what it is now I think, but there will be unrest in the ranks when you remove the genius in the company and replace him with the girl in the accounting department. Nvidia can be compared to the 90s Chicago Bulls until a few days ago. Chicago wins 6 championships during the 90s and suddenly someone gets the bright idea to remove Michael Jordan and then everything collapsed and they haven't won since and it's on those premises this stock is traded right now I think therefore the numbers don't seem to matter very much. So either you produce a new genius or you bring back the old genius but if you drag this out I think it will become problematic for everyone involved.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Tuotteita joiden kohde-etuutena tämä arvopaperi
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q4 - tulosraportti 24.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2027 Q3 - tulosraportti 17.11. | ||
2027 Q2 - tulosraportti 26.8. | ||
Vuosittainen yhtiökokous 2026 24.6. | ||
2027 Q1 - tulosraportti 20.5. | ||
2026 Q4 - tulosraportti 25.2. |
Välittäjätilasto
Dataa ei löytynyt
2027 Q3 - tulosraportti
UUTTA
2 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q4 - tulosraportti 24.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2027 Q3 - tulosraportti 17.11. | ||
2027 Q2 - tulosraportti 26.8. | ||
Vuosittainen yhtiökokous 2026 24.6. | ||
2027 Q1 - tulosraportti 20.5. | ||
2026 Q4 - tulosraportti 25.2. |
0,25 USD/osake
Viimeisin osinko
0,32%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenIn these times it is worth remembering why we believe in NVIDIA for the long term. Part of the potential lies in what the combination of future computing power, AI models and biological knowledge can make possible — and how NVIDIA may choose to monetize it. NVIDIA and Eli Lilly have announced a joint AI research laboratory with investments of up to $1 billion combined over five years, where biological and chemical models will be developed in close interplay with laboratory experiments. Together with Novo Nordisk and DCAI, NVIDIA is working around the Gefion supercomputer on, among other things, molecular design and models of cellular responses to drug candidates. The collaboration with the Chan Zuckerberg Initiative includes virtual cell models, biological datasets and evaluation of model quality. Biological complexity explains why the opportunities are vast and why development takes time. Proteins move, change shape and bind to other molecules. Inside the cell, gene activity, protein production, metabolism and chemical reactions influence each other. A change in one place can have consequences in many other places. Therefore, knowing a protein's structure is only part of the task. The time scales are also demanding. With a detailed molecular simulation using time steps of 2 femtoseconds, just one millisecond of the molecular trajectory requires 500 billion calculation steps, with many calculations in each step. This illustrates the challenge of this method; future models do not necessarily need to calculate every single atomic movement. At the same time, there is a lack of experimental data showing how different cells respond to stimuli, which can be used to develop and test the models. The collaborations can therefore both improve the technology and help identify the research problems where better computations create the greatest value. Models and computing power must evolve together. Even an extremely fast chip does not automatically create a correct model of biology. Conversely, a good model can be impractical if calculations take too long. When better chips are combined with more efficient algorithms and better biological models, increasingly demanding research tasks can become practically viable. As a hypothetical, optimistic scenario, this combined development over approximately 10–15 years could make selected calculation tasks 100 times faster, provided the results remain sufficiently reliable for the purpose. A task that would otherwise require ten years of computation could then be completed in about five weeks. This is a sample calculation and an estimated time horizon, not a forecast from NVIDIA. Valuable improvements may come much earlier, while laboratory work and clinical trials continue to follow their own timelines. The pace of development is therefore interesting. NVIDIA plans platform updates on an annual rhythm. Vera Rubin has begun shipping, while Rubin Ultra and Feynman lie further ahead in the development roadmaps. Additionally, the company has announced Rubin HPC, targeted at scientific simulations and expected to be available in 2028. Continuing in the next comment:Selling advanced chips and sharing tools today is strategic, but it does not permanently define the business model. For example, the BioNeMo Framework is currently free and open. This approach can drive adoption, experience, and demand for hardware. NVIDIA can thus profit from the research of many companies while building competencies and new opportunities. Over the longer term, NVIDIA could consolidate its own models, relevant data, and specialized research methods within its own research data centers, perhaps gaining an edge through early access to upcoming chip generations. Control over both hardware and software could provide advantages in customization and costs. Computing power would still cost money, and internal use would have to be attractive compared to selling the hardware. If this combined research capacity became sufficiently valuable, NVIDIA could choose to keep specific parts of the technology internal, use them for its own projects, and sell access to the computations. This could still be combined with extensive chip sales to others. If the platform also led to promising drug candidates of its own, the rights could be licensed in exchange for fees and royalties. Pharmaceutical companies could handle further development, clinical trials, approval, production, and sales. NVIDIA could thus generate revenue from hardware, the research platform, and concrete discoveries alike. Significant value can emerge through specialized models along the way toward a potentially more comprehensive simulator of cells and the human body. The entire vision does not need to be realized before the opportunities become interesting. This is an optimistic hypothesis regarding the opportunities NVIDIA can build—not a documented plan for a secret simulator. However, today's strategy can create the prerequisites for a different strategy later. The fact that it is attractive to sell the technology now does not mean it will always be most attractive to sell all parts of it. Jensen Huang has been central in shaping NVIDIA. However, belief in the company's future does not need to depend on him personally remaining at the helm the entire way. The technological direction is already visible in the chip pipeline, software platforms, and research collaborations, and the work is carried by an entire organization. The major breakthroughs still need to be created, but the foundation is laid, and the next stages are already under development. Jensen has helped chart the path; NVIDIA can continue the work of turning the vision into reality. Selected Sources NVIDIA and Eli Lilly's research collaboration, the collaboration with Novo Nordisk and DCAI, GROMACS for molecular simulation and timescales, NVIDIA's Vera Rubin platform and further development, as well as Rubin HPC for scientific simulations.
- ·6 t sittenIt is over! sell sell sell!!
- ·6 t sittenI am no expert but I think Nvidia is bought/sold for 2 reasons anthropic Jensen. I have been sitting and watching CNBC a lot the last few days and a lot has been about Jensen to be or not to be and if the Nvidia stock continues to plunge. And the new CEO's brutally bad conference speech from the board yesterday which was thought to be less gifted to comment on Jensen's situation since you don't know that much overall and they mean that is a part of the plunge we got to see today. So right now Nvidia is not traded on its numbers more on how the situation is and how it is handled. But as I said I am no expert we can hope for a day tomorrow.Nvidia is a winner and will probably not get much cheaper than what it is now I think, but there will be unrest in the ranks when you remove the genius in the company and replace him with the girl in the accounting department. Nvidia can be compared to the 90s Chicago Bulls until a few days ago. Chicago wins 6 championships during the 90s and suddenly someone gets the bright idea to remove Michael Jordan and then everything collapsed and they haven't won since and it's on those premises this stock is traded right now I think therefore the numbers don't seem to matter very much. So either you produce a new genius or you bring back the old genius but if you drag this out I think it will become problematic for everyone involved.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt











